New knowledge about treating multiple sclerosis

February 3, 2014

(Medical Xpress)—A study carried out at Victoria, and recently published online in the international scientific journal PLOS ONE, holds promise for patients suffering from secondary progressive MS, an advanced form of the disease, which causes nerve degeneration leading to impaired vision and coordination, and eventually, paralysis.

The study focused on understanding how a new MS drug, MIS416, developed by the New Zealand biotech company Innate Immunotherapeutics, is able to help with secondary progressive MS, a form of MS with few effective treatments.

The team of scientists includes Dr Anne La Flamme, an Associate Professor in Victoria's School of Biological Sciences and head of the MS Research Programme at the Malaghan Institute of Medical Research, PhD student Madeleine White, and Dr Gill Webster from Innate Immunotherapeutics.
"We know this drug works, but we are not sure why. This study has helped us understand the pathways that are driving the disease and how the medication alters the immune system, giving us a better idea of why MIS416 works as well as insight into how to treat patients and predict who will do better on this sort of medication," says Dr La Flamme.

Most people believe MS revolves around T cells, says Dr La Flamme, but the Victoria study reveals that targeting other cells in the central nervous system can significantly reduce advanced forms of MS.

Explore further: Cancer drug a possible treatment for multiple sclerosis

More information: White M, Webster G, O'Sullivan D, Stone S, La Flamme AC (2014) Targeting Innate Receptors with MIS416 Reshapes Th Responses and Suppresses CNS Disease in a Mouse Model of Multiple Sclerosis. PLoS ONE 9(1): e87712. DOI: 10.1371/journal.pone.0087712

Related Stories

Cancer drug a possible treatment for multiple sclerosis

February 21, 2013

(Medical Xpress)—A drug that is currently used for cancer can relieve and slow down the progression of the autoimmune disease multiple sclerosis (MS) in rats, according to a new study published in PLOS ONE. The discovery, ...

Patients curious about medical marijuana treatments

January 16, 2014

Ever since medical marijuana became legal in Illinois on Jan. 1, Loyola University Medical Center neurologist and multiple sclerosis specialist Dr. Matthew McCoyd has been inundated with questions from his patients.

Recommended for you

Motivation to bully is regulated by brain reward circuits

June 29, 2016

Individual differences in the motivation to engage in or to avoid aggressive social interaction (bullying) are mediated by the basal forebrain, lateral habenula circuit in the brain, according to a study conducted at the ...

New clues about the aging brain's memory functions

June 29, 2016

A European study led by Umeå University Professor Lars Nyberg, has shown that the dopamine D2 receptor is linked to the long-term episodic memory, which function often reduces with age and due to dementia. This new insight ...

New technology could deliver drugs to brain injuries

June 28, 2016

A new study led by scientists at the Sanford Burnham Prebys Medical Discovery Institute (SBP) describes a technology that could lead to new therapeutics for traumatic brain injuries. The discovery, published today in Nature ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.